Companies › Replimune
4 active drug programs in 11 registered trials: 6 Phase 2, 4 Phase 1, 1 Phase 3; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vusolimogene Oderparepvec Genetically modified Herpes Simplex Type 1 Virus (oncolytic immunotherapy) | – | Phase 3 | Advanced Melanoma; Angiosarcoma | Sep 2030 |
| RP2 Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation | – | Phase 2 | Hepatocellular Carcinoma; Metastatic Uveal Melanoma; Cancer; High-Risk Oral Precancerous Disease | Dec 2027 |
| RP1 Genetically modified herpes simplex virus type 1 (HSV-1) immunotherapy | – | Phase 2 | Cutaneous Squamous Cell Carcinoma; Non-Small Cell Lung Cancer (NSCLC); Merkel Cell Carcinoma; Squamous Cell Carcinoma | Jun 2028 |
| RP3 Genetically modified HSV-1 oncolytic virus | – | Phase 1 | Advanced Solid Tumor | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04050436 | RP1 | Phase 2 | Cutaneous Squamous Cell Carcinoma | Oncology | Sep 2025 |
| NCT05858229 | RP1 | Phase 1 | Squamous Cell Carcinoma | Oncology | Dec 2025 |
| NCT04336241 | RP2 | Phase 1 | Cancer | Oncology | Oct 2026 |
| NCT04735978 | RP3 | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2026 |
| NCT06623110 | RP2 | Phase 2 | High-Risk Oral Precancerous Disease | Oncology | Jan 2027 |
| NCT05733598 | RP2 | Phase 2 | Hepatocellular Carcinoma | Oncology | Dec 2027 |
| NCT03767348 | RP1 | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | Oncology | Jun 2028 |
| NCT04349436 | RP1 | Phase 1 | Merkel Cell Carcinoma | Oncology | Jul 2029 |
| NCT06898970 | Vusolimogene Oderparepvec | Phase 2 | Angiosarcoma | Oncology | Oct 2029 |
| NCT06581406 | RP2 | Phase 2 | Metastatic Uveal Melanoma | Oncology | Jan 2030 |
| NCT06264180 | Vusolimogene Oderparepvec | Phase 3 | Advanced Melanoma | Oncology | Sep 2030 |
Cash and short-term investments of $308m on 2026-09-30; operating cash outflow about $248m a year; runway about 15 months at that burn, to Dec 2027; 2 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Actinium Pharmaceuticals ALX Oncology Kura Oncology Oncolytics Biotech Cardiff Oncology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.